Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01850758 · ClinicalTrials.gov registry record · NA

Regenexx™ SD Versus Exercise Therapy for ACL Tears

A NA study of Anterior Cruciate Ligament Tear, sponsored by Regenexx.

Completed
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT01850758 is a NA study of Anterior Cruciate Ligament Tear that has completed, run by Regenexx. The registered enrollment target is 50 participants, below the 226-participant average among 11 other Anterior Cruciate Ligament Tear trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01850758, a NA study of Anterior Cruciate Ligament Tear, has completed, sponsored by Regenexx.

COMPLETED
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

The primary objective of this study is to compare the improvement in subject-reported clinical outcomes for Regenexx SD vs. Exercise Therapy treatment of partial and complete, non-retracted knee ACL ligament tears, from baseline to 3 months, with continued evaluation of efficacy and durability up to 24 months. Secondary objectives include evaluation of MRI evidence of tendon repair; incidence of post-operative complications, adverse events, re-injections, and surgical intervention; change in pain score and use of pain medications.

Interventions

  • PROCEDURE Regenexx SD
  • OTHER Exercise Therapy

Study Locations (1)

Colorado

  • Centeno-Schultz Clinic - Broomfield

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2013-05
Est. Completion 2022-03-08
Phase NA

Sponsor

Regenexx

13 total trials

What the Registry Record Tells You About NCT01850758

The ClinicalTrials.gov registry entry for NCT01850758 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 226-participant average among 11 other Anterior Cruciate Ligament Tear trials with a reported enrollment target (78% lower). The listed sponsor is Regenexx, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Anterior Cruciate Ligament Tear appearing as the primary indexed condition, and to 2 interventions - of which Regenexx SD is the first listed.

NCT01850758 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.

Frequently Asked Questions

What is clinical trial NCT01850758 about?

NCT01850758 is a clinical study titled "Regenexx™ SD Versus Exercise Therapy for ACL Tears". The primary objective of this study is to compare the improvement in subject-reported clinical outcomes for Regenexx SD vs. Exercise Therapy treatment of partial and complete, non-retracted knee ACL ligament tears, from baseline to 3 months, with continued evaluation of efficacy and durability up to...

What is the current status of trial NCT01850758?

This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2013-05. Estimated completion is 2022-03-08.

What conditions does trial NCT01850758 study?

This clinical trial studies the following conditions: Anterior Cruciate Ligament Tear.

What interventions are being tested in trial NCT01850758?

The interventions under investigation include: Regenexx SD (PROCEDURE), Exercise Therapy (OTHER).

Who is sponsoring clinical trial NCT01850758?

This trial is sponsored by Regenexx, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01850758 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Anterior Cruciate Ligament Tear

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.